Nautilus Biotechnology, Inc. (NAUT) Deep Dive Video

Summary

A cash-rich, founder-led proteomics moonshot: Nautilus is betting its Voyager™ single-molecule “Iterative Mapping” can leapfrog mass spec—if 2026–2027 commercialization execution holds.

View NAUT stock page · Read the NAUT research report

Loading the video player…